Trips And Traditional Knowledge - Reconciling Intellectual Property With Herbal Medicine And Indigenous Heritage
Author: LawSphereX
Category: Intellectual Property
Published:
Updated:
TRIPS AND TRADITIONAL KNOWLEDGE: RECONCILING
INTELLECTUAL PROPERTY WITH HERBAL MEDICINE AND INDIGENOUS HERITAGE Abraham Joseph, CHRIST (Deemed to be University), Delhi NCR I.
INTRODUCTION
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is a crucial international legal framework that sets minimum standards for the protection and enforcement of intellectual property (IP) rights across World Trade Organization (WTO) member countries. Established in 1994 under the Uruguay Round of the General Agreement on Tariffs and Trade (GATT), the TRIPS Agreement seeks to harmonize global IP laws by mandating compliance with its provisions. It covers various forms of IP, including patents, copyrights, and trademarks, ensuring that innovative and creative works receive adequate legal protection worldwide. One of the key areas affected by TRIPS is the pharmaceutical sector, including herbal medicines. Historically, traditional knowledge (TK) related to herbal medicines has been passed down through generations within indigenous and local communities.
However, the integration of such knowledge into the modern intellectual property system raises complex legal, ethical, and socio-economic concerns. The TRIPS Agreement obligates member countries to grant patents for inventions that meet the criteria of novelty, inventive step, and industrial applicability. This has led to challenges in defining and protecting traditional herbal medicine knowledge, which often does not fit neatly into these patent criteria. Herbal medicines, being an integral part of healthcare systems for centuries across different cultures, traditional herbal remedies have played a vital role in treating ailments and promoting overall well-being. Countries like China, India, and various African nations have rich traditions of herbal medicine, often rooted in indigenous knowledge systems such as Ayurveda, Traditional Chinese Medicine (TCM), and African ethno-medicine.
Even in Western medicine, herbal-derived compounds such as aspirin (from willow bark) and quinine (from cinchona bark) have demonstrated the therapeutic potential of natural remedies. In modern healthcare, herbal medicines continue to gain recognition due to their perceived safety, efficacy, and holistic benefits. The growing global demand for natural and plant-based medicines has fuelled the expansion of the herbal medicine industry, making it a lucrative market. However, the commercialization of herbal medicines also brings forth concerns regarding biopiracy—the unauthorized exploitation of indigenous knowledge by corporations and researchers who seek to patent traditional remedies without fair compensation to the original knowledge holders.
Articles 7 and 8 of the TRIPS Agreement serve as crucial guiding principles for interpreting and implementing its provisions,1 particularly in relation to public interest concerns such as access to medicines, technology transfer, and socio-economic development. These articles play a significant role in shaping the balance between intellectual property rights and broader policy objectives, ensuring that the enforcement of patents, including those for herbal medicines, does not undermine public health or the protection of traditional knowledge. Article 72 emphasizes that the objective of intellectual property protection should be to promote technological innovation while ensuring that benefits are shared in a way that contributes to economic and social welfare.
This provision is particularly relevant in the context of herbal medicines, as it highlights the need for a fair distribution of benefits derived from traditional knowledge and biodiversity. Many herbal remedies have been developed over centuries by indigenous and local communities, yet the modern patent system often fails to recognize their contributions, leading to concerns over biopiracy and misappropriation. Article 83 further strengthens this perspective by allowing member states to adopt necessary measures to protect public health and prevent the abuse of intellectual property rights. This principle provides flexibility for countries to implement safeguards such as compulsory licensing and stricter patentability criteria to prevent the unjust monopolization of traditional herbal formulations.
It also reinforces the importance of aligning intellectual property policies with broader societal interests, ensuring that patents do not restrict access to affordable medicines or hinder the sustainable use of biodiversity. Given the transformative nature of the TRIPS Agreement, which has established a unified global intellectual property framework, Articles 7 and 8 serve as a crucial counterbalance to ensure that innovation is not pursued at the expense of equity and fairness. The recognition of 1 Peter K. Yu, The Objectives And Principles Of The Trips Agreement, Houston Law Review (12/22/2009 8:18:51 PM), 4269-the-objectives-and-principles-of-the-trips-agreement. pdf.
2 TRIPS Agreement, art. 7
3 TRIPS Agreement, art. 8
these principles is especially relevant for herbal medicine patents, as it highlights the need for mechanisms that protect indigenous knowledge, prevent unfair exploitation, and promote equitable benefit-sharing in accordance with international agreements such as the Nagoya Protocol. II.
PATENTABILITY OF HERBAL MEDICINES UNDER TRIPS
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), administered by the World Trade Organization (WTO), establishes a comprehensive framework governing intellectual property protection on a global scale. Among its provisions, patent protection for pharmaceuticals—including herbal medicines—has remained a subject of intense debate, owing to the intrinsic complexities associated with traditional knowledge, bioprospecting, and the proprietary claims asserted over naturally occurring substances. This section critically examines the patentability criteria under TRIPS, the legal and procedural impediments in patenting herbal formulations, and significant case studies that have shaped international jurisprudence in this domain.
Pursuant to Article 27(1)4, patents shall be available for any inventions, whether products or processes, in all fields of technology, provided they satisfy the following fundamental requisites:
1. Novelty - A sine qua non for patent eligibility, mandates that the claimed invention must be
devoid of any prior disclosure in the public domain i.e., any invention or technology which has not been anticipated by publication in any document or used in the country or elsewhere in the world before the date of filing of patent application with complete specification5. In the context of herbal medicine, this requirement poses substantial challenges, given that the medicinal properties of numerous plants have been extensively documented in ancient pharmacopoeias, ethnobotanical literature, and indigenous knowledge systems. Where such knowledge is publicly accessible, it constitutes prior art, thereby rendering subsequent patent claims anticipated and, therefore, unenforceable. However, reformulations, novel extraction methodologies, or previously undiscovered therapeutic applications of known plants may, under certain conditions, meet the novelty threshold.
4 TRIPS Agreement, art. 27, cl.1.
5 The Patents Act,1970, § 2(i).
2. Inventive Step (Non-Obviousness) - Under patent jurisprudence, an invention is required
to involve an inventive step, meaning that feature of an invention that involves technical advance as compared to the existing knowledge or having economic significance or both and that makes the invention not obvious to a person skilled in the art6. Herbal formulations often fail this test due to the long-standing traditional usage of medicinal plants, where the mere isolation or concentration of active constituents does not suffice to establish non-obviousness. Courts and patent offices have frequently opined that mere optimization of dosage, combinations, or routine experimentation does not satisfy the inventive threshold unless it results in unexpected synergistic effects or a substantial enhancement in therapeutic efficacy.
3. Industrial Applicability (Utility) - An invention must be capable of industrial application,
meaning that it must produce a tangible, reproducible benefit in an industry. Herbal medicines frequently encounter scrutiny under this criterion, as patent applicants must furnish empirical data, clinical validation, and reproducibility evidence to substantiate their claims. Given the inherent variability in plant-derived compounds due to environmental factors, genetic diversity, and seasonal variations, ensuring consistency in herbal formulations poses a formidable challenge in meeting this patentability requisite. Despite the legal framework established under TRIPS, securing patent protection for herbal medicines is fraught with substantive and procedural obstacles. These impediments arise from the interplay of traditional knowledge governance, bioethical concerns, and the evidentiary burden required to establish patent eligibility. III.
TRADITIONAL KNOWLEDGE AND THE TRIPS AGREEMENT
The intersection of Traditional Knowledge (TK) and the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement is a subject of profound legal, ethical, and economic significance. Traditional Knowledge, which encompasses centuries old wisdom, practices, and innovations of indigenous and local communities, has been largely excluded from mainstream intellectual property (IP) regimes. The TRIPS Agreement, as the most comprehensive global treaty governing IP rights, establishes minimum standards for patentability and other protections. However, its structure predominantly favours Western, innovation-centric models of intellectual property, leaving TK vulnerable to exploitation and misappropriation. The
6 The Patents Act,1970, § 2(ja).
absence of explicit legal safeguards for TK under TRIPS has led to widespread concerns over biopiracy, the commodification of indigenous knowledge systems, and the inequitable extraction of value from traditional resources without due recognition or compensation to their rightful custodians. The recognition of self-determination rights for indigenous communities is intrinsically linked to their ability to exercise control over their Traditional Knowledge (TK) and genetic resources. 7 These rights are not isolated but form a complex legal and ethical framework that determines indigenous peoples' sovereignty over their cultural heritage, biodiversity, and sustainable development.
The lack of adequate legal protection for these rights under international intellectual property (IP) regimes has led to their widespread misappropriation, posing significant threats to indigenous identity, autonomy, and economic security. The Agreement is primarily designed to protect novel, inventive, and industrially applicable innovations through a market-driven approach to intellectual property which inherently excludes Traditional Knowledge, as TK is often: • Communal and Ancestral: TK is collectively owned by indigenous and local communities rather than being the product of a single inventor. • Evolved Over Generations: Unlike contemporary innovations that emerge from defined research and development (R&D) processes, TK is the result of gradual refinement across centuries, making it difficult to assign clear authorship.
• Publicly Available Yet Vulnerable: While TK exists in the public domain, it is often exploited by commercial entities that seek to privatize knowledge through patents and trademarks, leading to ethical and legal conflicts. This leads to a misappropriation of traditional knowledge, without the prior informed consent of the holders of knowledge as the agreement does not provide direct mechanisms for TK protection, which leaves indigenous communities at a disadvantage in defending their intellectual and cultural heritage against unauthorized appropriation. 8 Instead, they must rely on general provisions in Article 27. 3(b)9, which allows countries to exclude certain life forms 7 Grethel Aguilar, Access to genetic resources and protection of traditional knowledge in the territories of indigenous peoples, 4, Environmental Science & Policy, 241, 245, (2001). 8Id. at 250.
9 TRIPS Agreement, art. 27, cl. 3(b).
from patentability, and Articles 7 and 8, which emphasize public interest and socio-economic development. However, these provisions offer no substantive protection for TK, necessitating national and regional interventions to prevent its exploitation. As a response, various countries have sought alternative mechanisms for TK protection, such as sui generis legal frameworks, defensive protection strategies, and digital documentation initiatives like India's Traditional Knowledge Digital Library (TKDL). This necessitates a fundamental re-evaluation of global IP norms to integrate principles of equity, sustainability, and cultural sovereignty in the governance of knowledge systems. A.
Biopiracy and the Misappropriation of Indigenous Knowledge One of the most pressing consequences of TK’s exclusion from TRIPS is biopiracy, a phenomenon where corporations, research institutions, and individual’s appropriate biological resources and associated traditional knowledge without the consent of, or compensation to, the indigenous communities who have historically preserved and developed such knowledge. This issue manifests in several ways: • Unjust Patent Claims: Many patents have been granted on bioresources and medicinal formulations derived from TK, despite such knowledge being widely known within indigenous cultures. • Economic Dispossession: While corporations extract economic value from TK-based innovations, indigenous communities receive no financial or intellectual recognition, leading to concerns over inequitable access and benefit-sharing.
• Erosion of Cultural Sovereignty: The appropriation of TK undermines the cultural identity, heritage, and autonomy of indigenous populations by transforming their knowledge into commercial commodities. The asymmetry of power between traditional knowledge holders and multinational entities exacerbates the risks of biopiracy. Developed countries often possess the legal and financial infrastructure to secure patents and enforce intellectual property claims, while indigenous communities lack access to legal mechanisms to challenge such misappropriations effectively. Furthermore, national patent offices often operate without comprehensive databases on TK, allowing erroneous patents to be granted.
Efforts to combat biopiracy have led to increased calls for a revised IP governance model that recognizes TK as a legitimate and protectable form of knowledge. This includes integrating Access and Benefit-Sharing (ABS) principles, developing legally binding international agreements, and enhancing prior informed consent requirements for research and commercial utilization of TK. B. The Role of the Traditional Knowledge Digital Library (TKDL) in India The Traditional Knowledge Digital Library (TKDL) is a groundbreaking initiative by India, developed through the collaboration of the Council of Scientific and Industrial Research (CSIR) and the Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha, Sowa Rigpa, and Homoeopathy (AYUSH). 10 Its primary objective is to prevent the misappropriation of India’s rich traditional knowledge by ensuring its protection at international patent offices.
Traditional Knowledge (TK) holds immense value for indigenous and local communities, who rely on it for their livelihood. However, with the growing global interest in traditional medicine, TK faces increasing risks of exploitation and unauthorized commercialization. The controversial grant of a U. S. patent on the wound-healing properties of turmeric highlighted the pressing need for proactive measures to safeguard India’s TK. The extensive efforts and resources required to challenge and revoke this patent at the United States Patent and Trademark Office (USPTO) underscored the necessity for a structured mechanism to prevent such wrongful patent grants in the future. TKDL has emerged as a powerful tool against biopiracy and has gained international recognition for its effectiveness.
It has set a global precedent for Traditional Knowledge protection, particularly benefiting TK-rich nations by demonstrating the impact of preventive strategies and legal deterrence. By ensuring that patent examiners have access to TK-related prior art, TKDL helps prevent the wrongful grant of patents while simultaneously ensuring that traditional knowledge remains accessible and continues to benefit the communities that have preserved it for generations. Ø Key Functions and Strategic Importance of the TKDL: • Preventing the Granting of Erroneous Patents: By providing patent examiners with documented TK, the TKDL helps identify prior art and reject patent applications that 10 Traditional Knowledge Digital Library Unit (TKDL) (Apr. 2, 2025, 7:00 P. M. ), Traditional Knowledge Digital Library Unit (TKDL) | Council of Scientific & Industrial Research.
attempt to monopolize pre-existing knowledge. • Facilitating Global Collaboration: India has entered into agreements with major international patent offices, granting them access to TKDL to improve patent examination standards. • Strengthening Legal and Policy Frameworks: The TKDL has served as a model for other countries seeking to protect their indigenous knowledge and has influenced global debates on sui generis TK protection mechanisms. • Empowering Indigenous Communities: While the TKDL is a defensive mechanism, it highlights the need for proactive recognition of TK rights and ensures that traditional knowledge holders are not deprived of their intellectual heritage.
The success of the TKDL underscores the need for similar initiatives on a global scale, with international organizations, including the World Intellectual Property Organization (WIPO), advocating for the formal recognition of TK within the IP system. However, the lack of enforceable international norms continues to impede progress, making it imperative for developing nations to push for legal reforms that enshrine TK rights within multilateral trade agreements. IV.
JUDICIAL
ANALYSIS
OF BIOPIRACY The TRIPS Agreement, while setting international standards for intellectual property rights (IPR), does not provide explicit protection for TK, leading to conflicts between indigenous communities and multinational corporations (MNCs). Several judicial decisions across jurisdictions have shaped the legal landscape concerning biopiracy, emphasizing the need for legal reforms, equitable benefit-sharing, and stronger protection mechanisms for traditional knowledge holders.
1 Turmeric Case
Indian Council of Scientific and Industrial Research v. University of Mississippi Medical Centre, 1995 USA11 The Turmeric Patent Case stands as a significant milestone in the protection of Traditional
11 Anusree Bhowmick et al., A Brief Review on the Turmeric Patent Case with its Implications on the
Documentation on the Documentation of Traditional Knowledge, Volume 1, NDC E-BIOS, 83-88 (2021).
Knowledge (TK) against biopiracy. In 1995, the United States Patent and Trademark Office (USPTO) granted Patent No. 5,401,504 to the University of Mississippi Medical Center, covering the use of turmeric powder for wound healing, including both oral and topical applications. However, in 1996, the Council of Scientific and Industrial Research (CSIR), India, contested the patent, asserting that turmeric had been utilized in Indian traditional medicine for centuries to treat wounds, cuts, and rashes. CSIR contended that the claimed invention lacked novelty, as the therapeutic properties of turmeric were well-documented in traditional Indian medicinal practices. To substantiate its claim, CSIR presented extensive evidence, including 32 references from ancient Sanskrit, Urdu, and Hindi texts, along with a
1953 publication from the Indian Medical Association. Initially, the USPTO was reluctant to
revoke the patent, but after reviewing the evidence, it ultimately canceled the patent in 1997, acknowledging that turmeric’s medicinal use constituted prior art. This case underscored the critical need for systematic documentation of traditional knowledge to prevent its misappropriation under intellectual property laws. The outcome of this dispute played a pivotal role in the establishment of the Traditional Knowledge Digital Library (TKDL) in India, an initiative aimed at preventing unauthorized patents based on traditional medicinal practices. Furthermore, the turmeric patent revocation set a precedent for future legal battles against biopiracy, influencing subsequent cases, such as the challenge against patents on neem and other medicinal plants.
This legal victory was particularly significant as it marked the first successful revocation of a patent granted on traditional knowledge originating from a developing nation. It served as a turning point in global intellectual property discourse, reinforcing the need to safeguard indigenous knowledge systems from exploitation.
2 Basmati Rice Case
Agricultural and Processed Food Exports Development Authority v. Rice Tec Inc., 1997 USA12 RiceTec Inc. had applied for the trademark “Texmati” with the UK Trade Mark Registry, but its registration was successfully opposed by the Agricultural and Processed Food Exports Development Authority (APEDA), India. One of the key pieces of evidence presented by 12 Mukherjee, Utsav, A Study of the Basmati Case (India-US Basmati Rice Dispute): The Geographical Indication Perspective. Available at SSRN: https://ssrn.com/abstract=1143209 or http://dx.doi.org/10.2139/ssrn.1143209.
RiceTec in support of its application was US Patent No. 5,663,484, granted by the United States Patent and Trademark Office (USPTO) on September 2, 1997. This patent became the subject of legal contention, drawing opposition from India and Pakistan. Both nations objected to RiceTec’s claim, asserting that Basmati is a Geographical Indication (GI) rather than a generic term, as it refers to a specific aromatic, long-grain rice variety traditionally cultivated in the Indian subcontinent. RiceTec’s assertion of developing a novel rice variety was challenged on the grounds that Basmati had been cultivated in South Asia for centuries, rendering the patent invalid due to lack of novelty. The Indian government, along with various non-governmental organizations (NGOs), accused RiceTec of biopiracy, arguing that the company was misappropriating traditional knowledge without compensation.
Additionally, they contended that the patent violated the TRIPS Agreement by misleading consumers about the true origin of the rice. In 2000, following India's legal challenge, the USPTO initiated a re-examination of the patent. As a result, in 2002, 15 out of the 20 claims made by RiceTec were revoked, thereby preventing the company from marketing its rice under the Basmati name. The case had far-reaching implications as it helped safeguard the rights of Indian and Pakistani farmers, prevented misappropriation of traditional knowledge, and reinforced protections against biopiracy. Furthermore, the case played a key role in strengthening global GI laws, ultimately leading India to enact the Geographical Indications of Goods (Registration and Protection) Act, 1999, ensuring stronger legal protection for products linked to specific regions.
3 The Neem Case
WR Grace & co v. India13 Neem extracts have long been recognized for their potent pesticidal and antifungal properties, making them highly effective in protecting food crops. The oil derived from neem seeds is widely known for its medicinal benefits, including its use in treating common ailments such as colds and flu. The significance of neem has been documented in Indian texts for over 2,000 years, and local communities have traditionally utilized it in agriculture as a natural insect and pest repellent, as well as in human and veterinary medicine, cosmetics, and toiletries. In 1994, the European Patent Office (EPO) granted a patent (EPO Patent No. 436257) to the 13 Bio-piracy of Traditional Knowledge (Mar. 5, 2025, 5:00 P.M.), Bio-piracy of Traditional Knowledge.
U. S. -based corporation W. R. Grace & Co. and the U. S. Department of Agriculture (USDA) for a method involving the use of hydrophobic neem oil extract to combat plant fungal infections. However, in 1995, India’s Research Foundation for Science, Technology, and Ecology (RFSTE), along with various international organizations, challenged the patent, arguing that the antifungal properties of neem extracts had been well-known and traditionally used in Indian agriculture for centuries. The challengers contended that the patent lacked novelty and an inventive step, as the claimed method was merely a rediscovery of an existing practice. Following legal proceedings, the EPO ruled in 1999 that the patent claims were not innovative, as the use of neem extracts for fungal control had already been widely documented before the patent was filed.
As a result, the patent was officially revoked in May 2000. Later, in March 2006, the EPO dismissed an appeal filed in 2001 by W. R. Grace & Co. and the USDA, reaffirming its decision to annul the patent. This case became a landmark victory in the fight against biopiracy, reinforcing the importance of safeguarding traditional knowledge and preventing its unjust appropriation through intellectual property laws.
4. The Ayahuasca Case14
For centuries, Shamans of indigenous tribes in the Amazon basin have utilized the bark of Banisteriopsis caapi Mort. to prepare a sacred ceremonial drink known as Ayahuasca. Meaning “wine of the soul,” Ayahuasca plays a central role in religious and healing rituals, assisting Shamans in diagnosing and treating illnesses, communicating with spirits, and foreseeing future events. In 1986, an American researcher, Loren Miller, was granted U. S. Plant Patent No. 5,751, which conferred exclusive rights over a purportedly distinct variety of B. caapi Mort. , which he had collected from a domestic garden in the Amazon and named “Da Vine. ” The patent was based on the claim that Da Vine was a new and distinct variety, primarily due to the differences in flower color and its potential medicinal properties.
The Coordinating Body of Indigenous Organizations of the Amazon Basin (COICA)—representing over 400 indigenous tribes— along with other advocacy groups, strongly opposed the patent, arguing that Ayahuasca had been cultivated and used for medicinal and spiritual purposes by Amazonian tribes for generations. They contended that Miller had not “discovered” the plant, and granting him exclusive rights amounted to the misappropriation of indigenous traditional knowledge. In
14 Supra Note 13.
response to these protests, the United States Patent and Trademark Office (USPTO) conducted a reexamination, which resulted in the revocation of the patent on November 3, 1999. However, following a subsequent appeal by the inventor, the USPTO reconsidered its decision, and on April 17, 2001, the patent rights were reinstated. This case remains a controversial example of biopiracy, raising significant concerns regarding the ethical and legal implications of granting intellectual property rights over traditionally known plant species.
5. The Hoodia (Hoodia gordonii (Masson) Sweet ex Decne) Case15
For generations, the San people of the Kalahari Desert have relied on the Hoodia cactus for its natural appetite-suppressing properties, enabling them to endure extended hunting expeditions without food or water. However, in 1995, the South African Council for Scientific & Industrial Research (CSIR) patented the active appetite-suppressing compound P57 derived from Hoodia. Subsequently, in 1997, CSIR granted an exclusive license to the British biotechnology firm Phytopharm to further develop the compound. The following year, Pfizer acquired commercialization rights to P57 for a $32 million deal, aiming to develop it as a pharmaceutical solution for obesity management. By 2001, the San people became aware that their traditional knowledge had been appropriated without their consent, leading them to initiate legal action against CSIR and the pharmaceutical companies involved.
They contended that the commercialization of their indigenous knowledge without prior informed consent constituted biopiracy, thereby violating the principles of the Convention on Biological Diversity (CBD). While CSIR asserted that it had intended to share the benefits, complexities arose in determining the rightful beneficiaries, given that the San people are a historically dispersed and nomadic community. Following legal proceedings, a landmark agreement was reached in 2002, granting the San community a share in future royalties derived from Hoodia’s commercialization. However, with Hoodia flooding the gray market through unregulated sales, the actual financial benefits received by the San people remain ambiguous and largely unfulfilled. This case remains a prominent example of the ethical and legal challenges in protecting traditional knowledge from commercial exploitation.
15 Supra Note 13.
6. The Phyllanthus amarus Schum.et Thonn. Patent16
The U. S. Patent No. 7,829,124 B2, titled "Use of Phyllanthus Constituents for Treating or Preventing Infections Caused by Hepatitis B Viruses," was granted on November 9, 2010, to Michael Ott and Michael P. Manns. This patent pertains to the utilization of bioactive compounds derived from the Phyllanthus plant for the prevention and treatment of hepatitis B virus (HBV) infections, particularly those caused by drug-resistant strains. The invention explores the inhibitory effects of Phyllanthus extracts on HBV DNA synthesis and gene expression, presenting a natural and alternative therapeutic approach to conventional antiviral treatments. A significant challenge in hepatitis B treatment is the emergence of drug-resistant viral strains, particularly those that exhibit resistance to nucleoside analogues such as Lamivudine and Famciclovir.
Conventional antiviral therapies often lose efficacy over time due to viral mutations, necessitating the development of alternative treatment strategies. The research underlying this patent demonstrates that certain Phyllanthus species—including Phyllanthus amarus, Phyllanthus niruri, and Phyllanthus emblica—contain bioactive compounds capable of inhibiting viral replication in both standard and drug-resistant HBV strains. The mechanism of action involves blocking HBV DNA synthesis and suppressing viral gene expression, thereby disrupting the virus’s replication cycle within liver cells. The efficacy of Phyllanthus extracts was confirmed through in vitro experiments using HuH7 cell cultures, which exhibited dose-dependent inhibition of viral DNA synthesis.
Notably, the extract was found to be effective against the YMDD variant of HBV, a strain resistant to Lamivudine, further underscoring its potential as a viable antiviral therapy. The Phyllanthus genus comprises approximately 700 species distributed across tropical and subtropical regions of Asia, Africa, and South America. These plants are rich in alkaloids, tannins, lignans, sesquiterpenes, and triterpenes, many of which have demonstrated antiviral, antimicrobial, and immunomodulatory properties. Traditional medicinal systems, including Ayurveda and Chinese medicine, have long utilized Phyllanthus species to treat hepatic disorders, such as jaundice and hepatitis. The patent outlines various pharmaceutical applications of Phyllanthus extracts, which may be formulated into infusions, injections, tablets, ointments, healing packs, and food additives. These formulations provide multiple
16 Id.
modes of administration, including oral, topical, and parenteral (injections/infusions). Additionally, the extract can be co-administered with antiviral agents such as interferon-α, interferon-β, interferon-γ, and ribavirin to enhance its therapeutic efficacy. One of the key advantages of Phyllanthus-based treatments is their natural origin, which may result in fewer adverse effects compared to synthetic antiviral drugs. This makes them an attractive alternative for long-term management of chronic HBV infections. Furthermore, given the widespread availability of Phyllanthus plants in various regions worldwide, this approach holds promise as a cost-effective treatment for resource-limited settings, where access to expensive antiviral drugs remains a significant challenge. In conclusion, the U. S. Patent No.
7,829,124 B2 introduces a novel herbal-based therapy for hepatitis B infections, particularly those caused by drug-resistant strains. The ability of Phyllanthus extracts to inhibit viral replication and gene expression underscores their potential as a complementary or standalone antiviral treatment. This research provides a foundation for further exploration into plant-derived therapies for hepatitis B, with the potential to significantly impact global public health. V.
LEGAL AND POLICY RESPONSES TO PROTECT HERBAL MEDICINE
KNOWLEDGE The increasing commercialization of plant-based treatments has necessitated the development of robust legal frameworks at the national level to safeguard traditional knowledge (TK) associated with herbal medicine. Several countries have implemented specialized legislation to prevent the misappropriation of indigenous medicinal knowledge and ensure fair benefitsharing mechanisms. Ø India: The Biological Diversity Act, 2002 & Traditional Knowledge Digital Library (TKDL) India has established The Biological Diversity Act, 2002, which aligns with the Convention on Biological Diversity (CBD) to regulate access to biological resources and associated TK. The Act mandates prior informed consent (PIC) and requires benefit-sharing agreements when commercial entities seek to utilize traditional herbal knowledge for profit.
Foreign individuals and corporations require approval from the National Biodiversity Authority (NBA) before accessing biological resources or associated knowledge. 17 Further, no person or entity can apply for an intellectual property right (IPR) related to a biological resource or associated TK without prior approval from the NBA. 18 Additionally, the establishment of Biodiversity Management Committees (BMCs) at the local level ensures community participation in decision-making. It mandates fair and equitable benefit-sharing (ABS) with indigenous communities when their knowledge is used commercially. 19 In parallel, the Traditional Knowledge Digital Library (TKDL) was created to prevent the unauthorized patenting of India's traditional medicinal knowledge, enabling patent offices worldwide to identify prior art and reject biopiracy claims. Ø Brazil: Biodiversity Law (Law No.
13,123/2015) Brazil’s Biodiversity Law recognizes indigenous ownership of medicinal knowledge and requires that any commercial use of TK be subject to prior informed consent and Access Benefit-Sharing (ABS) agreements. 20 This law imposes strict penalties for biopiracy and mandates that a percentage of profits derived from traditional herbal medicine be allocated to indigenous communities. Additionally, Brazil maintains national and community registries documenting traditional medicinal practices, reinforcing indigenous control over their intellectual heritage. Ø Peru: Protection of Indigenous Knowledge Related to Biological Resources (2002) Peru’s legislative approach to TK protection is one of the most advanced globally.
The Law on the Protection of Indigenous Knowledge Related to Biological Resources (2002) established a national database to prevent unauthorized patents and explicitly recognizes indigenous ownership of TK. This law enables indigenous communities to negotiate licensing agreements with pharmaceutical companies and research institutions, ensuring fair compensation. Ø South Africa: Indigenous Knowledge Act (2019) South Africa’s Indigenous Knowledge Act strengthens protections for traditional medicinal
17 Biological Diversity Act, 2002, § 3.
18 Biological Diversity Act, 2002, § 6.
19 Biological Diversity Act, 2002, § 21.
20 Biodiversity Law (Law No. 13,123/2015), 2015, art. 17.
knowledge by legally recognizing it as intellectual property (IP). The Act creates a National Indigenous Knowledge Management System that registers and safeguards medicinal formulations, while also establishing legal pathways for benefit-sharing arrangements when TK is commercialized. International Legal Frameworks and Negotiations to Protect Herbal Medicine Knowledge: The global community has recognized the urgency of protecting TK through various international agreements and policy discussions, primarily under the CBD, Nagoya Protocol, and WIPO frameworks. Ø Convention on Biological Diversity (CBD) The CBD (1992) marked a pivotal moment in the recognition of sovereign rights over genetic resources and associated TK.
It introduced key provisions aimed at protecting traditional herbal medicine knowledge: • Article 8(j): Mandates the preservation, protection, and equitable use of TK, requiring parties to involve indigenous and local communities in biodiversity conservation efforts. 21 • Article 10(c): Calls for the recognition and protection of customary uses of biological resources by indigenous communities. • Article 15: Establishes that access to genetic resources requires prior informed consent (PIC) and must adhere to mutually agreed terms (MAT), ensuring that benefits arising from the use of traditional medicinal knowledge are fairly distributed. The CBD applies to Contracting Parties, that is to say to States because that is in effect what is involved when the Parties realize a transaction in which access to genetic resources is negotiated.
22 21 Freedom-Kai Phillips, ‘Intellectual Property Rights in Traditional Knowledge: Enabler of Sustainable Development’ (2016) 32(83) Utrecht Journal of International and European Law 1, DOI: http://dx. doi. org/10. 5334/ujiel. 283.
22 Supra Note 7 at 244.
Ø The Nagoya Protocol (2010) The Nagoya Protocol provides an enforceable framework for access and benefit-sharing (ABS) arrangements related to TK. It builds upon the CBD by requiring: • Prior Informed Consent (PIC): Researchers and companies must obtain formal approval from indigenous communities before utilizing their medicinal knowledge. • Mutually Agreed Terms (MAT): Ensures that communities are fairly compensated through benefit-sharing agreements, including monetary benefits, technology transfer, and capacity-building initiatives. • Compliance Obligations: Requires signatory nations to implement domestic legislation that enforces ABS principles and prevents biopiracy.
A landmark example demonstrating the effectiveness of the Nagoya Protocol is the Kani Tribe’s successful negotiation with the Indian pharmaceutical industry over the use of the Arogyapacha plant in developing the Jeevani drug, which led to an equitable benefit-sharing arrangement. WIPO and the Protection of Traditional Knowledge The World Intellectual Property Organization (WIPO) has played a crucial role in integrating TK protection into the global intellectual property system. Through its Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore (IGC), WIPO has been working towards developing an international legal instrument that recognizes TK as a form of intellectual property and establishes exclusive rights for indigenous communities over their medicinal knowledge.
WIPO also promotes the creation of Traditional Knowledge Databases, similar to India's TKDL, enabling countries to document herbal medicine knowledge and prevent unauthorized patenting. VI.
FUTURE DIRECTIONS AND REFORMS IN THE TRIPS AGREEMENT
As global awareness of biopiracy and misappropriation of TK grows, there have been increasing calls for reforms and amendments to TRIPS to integrate mechanisms that safeguard traditional medicinal knowledge while ensuring equitable benefit-sharing.
Ø Recognition of Traditional Knowledge as a Form of Intellectual Property One of the major criticisms of TRIPS is that it only recognizes modern patent systems and fails to accommodate non-Western knowledge systems, such as traditional medicinal knowledge passed down through generations. Future reforms should recognize traditional knowledge (TK) as a distinct form of intellectual property (IP) within TRIPS; allow collective ownership of TK, particularly in indigenous communities, as opposed to the current individual-centric patent system and expand TRIPS Article 27. 3(b) to include sui generis protection mechanisms (customized legal frameworks) for TK.
Several developing nations, particularly India, Brazil, and South Africa, have proposed the creation of a new category of intellectual property rights (IPRs) specific to traditional knowledge, ensuring indigenous communities retain control over their medicinal knowledge. Ø Mandatory Disclosure of Origin for Patents Involving Traditional Knowledge One key proposal to prevent biopiracy is the introduction of a mandatory disclosure requirement in TRIPS, which would require patent applicants to: • Identify the source of biological materials used in herbal medicines. • Provide evidence of prior informed consent (PIC) from indigenous communities. • Demonstrate a fair and equitable benefit-sharing (ABS) agreement, ensuring that local communities receive compensation.
This proposal aligns with the Nagoya Protocol (Article 5, 6, and 15) and would help close legal loopholes that allow corporations to patent herbal remedies without compensating indigenous peoples. Ø Strengthening the Role of WIPO’s Intergovernmental Committee (IGC) on Traditional Knowledge The World Intellectual Property Organization (WIPO) has been working towards an international legal instrument for protecting traditional knowledge. However, TRIPS does not currently recognize WIPO’s recommendations on traditional knowledge protection. Future reforms could:
Establish binding obligations within TRIPS that integrate WIPO’s framework on TK protection. • Create an international TK database, similar to India’s Traditional Knowledge Digital Library (TKDL), to prevent fraudulent patents. Ø Encouraging Open Innovation Models for Herbal Medicines To promote affordability and access, policymakers could explore alternative innovation models such as: • Open-source drug discovery for traditional herbal remedies. • Public-private partnerships (PPPs) to fund research while ensuring fair benefit-sharing with indigenous communities. • Patent pools that allow multiple companies to share rights over herbal medicine formulations. Ø Limiting the Duration of Patents for Herbal Medicines Unlike synthetic drugs, herbal medicines have been used for centuries.
A potential TRIPS amendment could: • Reduce patent duration for herbal medicines from 20 years to 10-15 years. • Introduce compulsory licensing mechanisms that allow governments to override patents in cases of public health emergencies.
VII.
CONCLUSION
The protection of traditional knowledge (TK) within intellectual property (IP) frameworks remains a significant challenge, as the current international legal landscape fails to provide comprehensive safeguards against the misappropriation of indigenous medicinal knowledge. The TRIPS Agreement, which governs global patent laws, does not explicitly recognize TK, nor does it mandate disclosure of origin, prior informed consent, or benefit-sharing, all of which are crucial to preventing biopiracy. As a result, corporations and researchers have frequently patented bioresources and associated TK without acknowledging or compensating indigenous communities, as seen in cases involving turmeric, neem, Basmati rice, and Hoodia.
Efforts at the international level, including the Convention on Biological Diversity (CBD) and the Nagoya Protocol, aim to address these concerns by establishing access and benefit-sharing (ABS) mechanisms. However, enforcement remains inconsistent, particularly due to conflicts between biodiversity laws and patent regimes. While some nations have implemented national laws to protect TK such as India’s Biological Diversity Act and the Traditional Knowledge Digital Library (TKDL), these measures are limited in scope and do not apply universally. Additionally, ongoing negotiations within the World Intellectual Property Organization (WIPO) Intergovernmental Committee (IGC) on Genetic Resources, Traditional Knowledge, and Folklore have yet to produce a binding international treaty that explicitly safeguards indigenous medicinal knowledge.
Legal reforms must prioritize the incorporation of TK protection within patent laws, particularly through mandatory disclosure of genetic resource origins in patent applications, strengthened examination standards for patents involving traditional medicinal knowledge, and binding benefit-sharing obligations. Amendments to TRIPS should include provisions ensuring that TK-based innovations remain accessible to indigenous communities and are not subject to monopolistic patent control. Moreover, the need to balance innovation with equitable access to medicines necessitates a framework that fosters research while preventing the exploitation of traditional medicinal knowledge. In conclusion, a harmonized legal and policy framework is imperative to ensure that indigenous communities retain control over their traditional knowledge.
Strengthened international cooperation, stricter patent examination protocols, and binding benefit-sharing mechanisms will be essential to combat biopiracy effectively. Without these reforms, the current system will continue to allow misappropriation and commercial exploitation of traditional medicinal knowledge, denying rightful recognition and benefits to indigenous knowledge holders.